Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7235
    -0.0018 (-0.25%)
     

  • CRUDE OIL

    85.29
    -0.07 (-0.08%)
     

  • Bitcoin CAD

    88,149.45
    +557.70 (+0.64%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,400.90
    -6.90 (-0.29%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ futures

    17,907.00
    +25.75 (+0.14%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6811
    -0.0013 (-0.19%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

Germany for now has enough remdesivir for COVID-19 therapy -govt

Reuters
Updated ·1 min read

BERLIN, July 1 (Reuters) - Germany has for now secured enough supplies of remdesivir, which is set to become the first COVID-19 treatment approved in Europe, and is banking on developer Gilead to meet future needs, the country's health ministry said on Wednesday.

"The federal government has early on secured remdesivir for the treatment of coronavirus patients. Currently, there are still sufficient reserves," the ministry told Reuters in a written statement.

With a conditional market approval, which is expected to be issued by the EU Commission this week, comes an obligation to deliver sufficient quantities in the future, it added.

"We trust Gilead will meet this obligation," the ministry said. (Reporting by Andreas Rinke Writing by Ludwig Burger)